A woman from Washington with cystic fibrosis suffers years of worsening symptoms stemming from a skin infection.
Born with Cystic Fibrosis (CF), Brianna Strand was used to being treated for the routine lung infections associated with the disease.
After contracting an antibiotic-resistant infection, a woman from North Carolina faces surgery as a final treatment option.
"Mary is currently on the maximum dosage… and if it stops working, her last resort will be to have surgery."
A 19-year-old college hopeful and cancer survivor dies from an antibiotic-resistant infection.
"During the procedure her blood oxygen levels dropped significantly and she went into septic shock."
A seemingly harmless ear infection turns into a life-threatening MRSA scare for a 2 ½ year old boy.
"But my wife and I were fearful, knowing that with every failed attempt to cure the infection the situation became more critical."
Because of antibiotic resistance, many bacterial infections have become impossible to treat. New antibiotics are desperately needed to save patients' lives, but few new drugs are in pharmaceutical companies' research and development (R&D) pipelines. Low returns on investments and an unpredictable and often infeasible approval pathway at the U.S. Food and Drug Administration (FDA) have caused many companies to leave the antibiotics market.
IDSA is working to counter this decline through the 10 x '20 Initiative (read our statement). The initiative seeks a global commitment to create an antibiotic R&D enterprise powerful enough to produce 10 new systemic antibiotics by the year 2020. This effort has the potential to save thousands of lives each year. To achieve our goal, IDSA is working with a broad range of stakeholders in the United States and globally. We need your help!
Join other medical
societies, public health organizations, and universities in endorsing the 10 x
'20 initiative. See
who else has joined us >>
Take Action: Tell Congress to join efforts to combat antibiotic resistance and learn more about what you can do to stop bad bugs. Get Smart >>
If you or a loved
one have been devastated by an antibiotic resistant bacterial infection and you
would like to share
your story, please contact Diana
Spread the word
IDSA coordinated a letter,
joined by 47 other health groups, to President-elect Trump urging that federal
efforts to combat antimicrobial resistance be maintained in the years ahead.
As the House prepared to vote on
a new version of the 21st Century Cures Act, IDSA wrote in support
and highlighted the provisions addressing antibiotic R&D, the future
research workforce, and the opioid epidemic as essential.
Tenzin Lobsang Kunor
Tenzin Lobsang Kunor was in the last semester of college, had just been admitted to graduate school, and offered an assistantship connected to the program. Best of all, he recently started dating the love of his life. He felt happy, carefree, and enthusiastic about th
Dr. Gentry prescribed ciprofloxacin, which was temporarily holding the infection at bay. Dr. Gentry suggested Zerbaxa®, a combination antibiotic therapy that was not FDA-approved to treat pseudomonas but had shown promising test results. Because Zerbaxa® is very difficult to obtain, Roger was put on a waiting list. Several weeks passed, and his infection became increasingly resistant to the ciprofloxacin. Finally, doctors obtained the Zerbaxa®. Within one day of treatment, Roger’s white blood cell count dropped dramatically and approached the normal range. Doctors
remained skeptical about Roger’s recovery as his infection could develop a resistance to Zerbaxa® as well. But his white blood cell count continued to improve, so Dr. Gentry tapered him off the Zerbaxa® to see if the infection would return. It did not, and Roger was able to go home, nearly four months after his initial surgery. He has recovered, with no signs of re-infection. Roger’s immune system was severely weakened after extended courses of antibiotics, and he has been briefly readmitted to the hospital several times for minor illnesses. But he recently overcame a cold on his own without being hospitalized.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2017 Infectious Diseases Society of America